Altimmune Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass enrollment ongoing in impact phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (mash), with topline 24-week data expected q1 2025 preclinical study results showed a direct anti-fibrotic effect of pemvidutide in a non-steatotic model of liver fibrosis cash, cash equivalents and short-term investments of $198.0 million at december 31, 2023 webcast to be held today, march 27, 2024, at 8:30 am et gaithersburg, md., march 27, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided a business update.

Gaithersburg, md., march 20, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on wednesday, march 27, 2024 and will provide a business update.

New york , march 5, 2024 /prnewswire/ -- why: rosen law firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of altimmune, inc. (nasdaq: alt) resulting from allegations that altimmune may have issued materially misleading business information to the investing public. so what: if you purchased altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New york , march 3, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of altimmune, inc. ("altimmune" or the "company") (nasdaq: alt).  such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.

New york--(business wire)---- $alt #classaction--attorney advertising--bronstein, gewirtz & grossman, llc is investigating potential claims on behalf of purchasers of altimmune, inc. (“altimmune” or “the company”) (nasdaq: alt). investors who purchased altimmune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/alt. investigation details: altimmune's stock price has more than tripled since november, after the company reported that data.

Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development.

Biotech stocks can offer some of the most explosive, exciting opportunities on the market. That is, if you find the right one.

Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon dual agonist similar to the weight-loss treatments Mounjaro and Zepbound by  Eli Lilly and Co. NYSE: LLY.

Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of retiring baby boomers, demand for better care, pharmaceutical companies nearing patent expirations, a resurgence of mergers and acquisitions, and even new treatments that'll help you shed weight.

Altimmune (ALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion by 2030. Results from the phase 2b IMPACT study, using pemvidutide for the treatment of patients with MASH, expected to be released Q1 of 2025.

The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.

Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company's stock surged by more than 580% from its lowest level in 2023.

Altimmune (NASDAQ: ALT ) stock is rising higher on Monday but it's not actually due to any news from the clinical-stage biopharmaceutical company. Instead, a clinical trial update from rival Zealand Pharma is behind the increase in ALT stock today.